364-DAY BRIDGE CREDIT AGREEMENT Dated as of May 8, 2018 among TAKEDA PHARMACEUTICAL COMPANY LIMITED, as Borrower, VARIOUS FINANCIAL INSTITUTIONS, as Lenders, and JPMORGAN CHASE BANK, N.A., as Administrative Agent JPMORGAN CHASE BANK, N.A., SUMITOMO...Bridge Credit Agreement • November 16th, 2018 • Takeda Pharmaceutical Co LTD • Pharmaceutical preparations • New York
Contract Type FiledNovember 16th, 2018 Company Industry JurisdictionThis 364-Day Bridge Credit Agreement (this “Agreement”) dated as of May 8, 2018 is among Takeda Pharmaceutical Company Limited, a joint-stock company organized and existing under the laws of Japan (the “Borrower”), the Lenders (as defined below) that are parties hereto, and JPMorgan Chase Bank, N.A., as Administrative Agent (as defined below) for the Lenders.
English Translation solely for Information Purposes – Japanese language original shall govern and control] SUBORDINATED SYNDICATED LOAN AGREEMENT dated October 26, 2018 among TAKEDA PHARMACEUTICAL COMPANY LIMITED as Borrower SUMITOMO MITSUI BANKING...Syndicated Loan Agreement • November 16th, 2018 • Takeda Pharmaceutical Co LTD • Pharmaceutical preparations • Tokyo
Contract Type FiledNovember 16th, 2018 Company Industry JurisdictionThis Agreement is made as of October 26, 2018 among TAKEDA PHARMACEUTICAL COMPANY LIMITED, as the borrower (the “Borrower”) and the financial institutions set out in the lenders column of Attachment 1 as the lenders (collectively the “Lenders” and each a “Lender”), and Sumitomo Mitsui Banking Corporation, as the agent (the “Agent”), as follows:
COLLABORATION AGREEMENTCollaboration Agreement • November 16th, 2018 • Takeda Pharmaceutical Co LTD • Pharmaceutical preparations • New York
Contract Type FiledNovember 16th, 2018 Company Industry JurisdictionThis COLLABORATION AGREEMENT (the “Agreement”) is entered into on December 14, 2009 (the “Effective Date”) by and between Seattle Genetics, Inc., a Delaware corporation, with its principal place of business at 21823 30th Drive SE, Bothell, WA 98021 (“SGI”), and Millennium Pharmaceuticals, Inc., with its principal place of business at 40 Landsdowne Street, Cambridge, MA 02139 (“MPI”). SGI and MPI are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”